Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab-Nivolumab in Local-Regionally Advanced NSCLC
NCT04013542Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2019
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab and nivolumab in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events up to 2 years. Started Sep 2019; status: active, not recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04013542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013542.